Lupin Limited
LUPIN
Classifica tra le azioni
#2100
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
Prezzo delle azioni
$21.44
Capitalizzazione di mercato
$9.81B
Variazione (1 giorno)
0.19%
Variazione (1 anno)
-2.83%
Paese
IN
Scambia Lupin Limited (LUPIN)
Categoria
Healthcare
Rapporto P/B per Lupin Limited (LUPIN)
Rapporto P/B al October 2026 TTM: 4.01
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Lupin Limited, il rapporto P/B attuale (TTM) è 4.01. Alla fine del 2024, era pari a 5.20.
Storico del rapporto P/B per Lupin Limited da 2004 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 4.01 | -22.82% |
| 2025 | 5.20 | 0.14% |
| 2024 | 5.20 | 119.66% |
| 2023 | 2.37 | -15.25% |
| 2022 | 2.79 | -16.71% |
| 2021 | 3.35 | 57.38% |
| 2020 | 2.13 | -15.55% |
| 2019 | 2.52 | -2.50% |
| 2018 | 2.59 | -46.46% |
| 2017 | 4.83 | -19.02% |
| 2016 | 5.96 | -41.29% |
| 2015 | 10.16 | 68.45% |
| 2014 | 6.03 | 10.74% |
| 2013 | 5.45 | -7.55% |
| 2012 | 5.89 | 4.11% |
| 2011 | 5.66 | 3.72% |
| 2010 | 5.46 | 37.73% |
| 2009 | 3.96 | 24.56% |
| 2008 | 3.18 | -42.95% |
| 2007 | 5.57 | -14.64% |
| 2006 | 6.53 | 45.52% |
| 2005 | 4.49 | -25.91% |
| 2004 | 6.06 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 25.60% |
IN
|
